JP2022506761A5 - - Google Patents
Info
- Publication number
- JP2022506761A5 JP2022506761A5 JP2021524345A JP2021524345A JP2022506761A5 JP 2022506761 A5 JP2022506761 A5 JP 2022506761A5 JP 2021524345 A JP2021524345 A JP 2021524345A JP 2021524345 A JP2021524345 A JP 2021524345A JP 2022506761 A5 JP2022506761 A5 JP 2022506761A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody construct
- item
- seq
- heavy chain
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024144789A JP2024170456A (ja) | 2018-10-29 | 2024-08-26 | ＩｇＡ抗体構築物を含む組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18203183 | 2018-10-29 | ||
| US201862752641P | 2018-10-30 | 2018-10-30 | |
| US62/752,641 | 2018-10-30 | ||
| PCT/US2019/058648 WO2020092427A1 (en) | 2018-10-29 | 2019-10-29 | COMPOSITIONS AND METHODS COMPRISING IgA ANTIBODY CONSTRUCTS |
| EP18203183.1 | 2019-10-29 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144789A Division JP2024170456A (ja) | 2018-10-29 | 2024-08-26 | ＩｇＡ抗体構築物を含む組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022506761A JP2022506761A (ja) | 2022-01-17 |
| JP2022506761A5 true JP2022506761A5 (https=) | 2022-10-31 |
Family
ID=70462698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524345A Pending JP2022506761A (ja) | 2018-10-29 | 2019-10-29 | ＩｇＡ抗体構築物を含む組成物および方法 |
| JP2024144789A Pending JP2024170456A (ja) | 2018-10-29 | 2024-08-26 | ＩｇＡ抗体構築物を含む組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024144789A Pending JP2024170456A (ja) | 2018-10-29 | 2024-08-26 | ＩｇＡ抗体構築物を含む組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210332131A1 (https=) |
| EP (1) | EP3873942A4 (https=) |
| JP (2) | JP2022506761A (https=) |
| KR (1) | KR20210096612A (https=) |
| CN (1) | CN113260632A (https=) |
| AU (1) | AU2019369397A1 (https=) |
| CA (1) | CA3118312A1 (https=) |
| GB (1) | GB2596411B (https=) |
| WO (1) | WO2020092427A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114096559B (zh) * | 2019-03-27 | 2026-03-20 | 蒂嘉特克斯公司 | 工程化iga抗体及其使用方法 |
| WO2022087416A1 (en) * | 2020-10-22 | 2022-04-28 | Actinium Pharmaceuticals, Inc. | Combination radioimmunotherapy and cd47 blockade in the treatment of cancer |
| WO2022125439A2 (en) * | 2020-12-07 | 2022-06-16 | The Regents Of The University Of California | Innate immune cell silencing by sirp-alpha engager |
| CN116731161A (zh) * | 2021-09-18 | 2023-09-12 | 南开大学 | 工程化IgG和IgA嵌合的“四叶草型X抗体” |
| AU2023219697A1 (en) * | 2022-02-09 | 2024-08-22 | Exelixis, Inc. | Multispecific binding agents and uses thereof. |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0226878D0 (en) * | 2002-11-18 | 2002-12-24 | Univ Warwick | Antibodies |
| US9296820B2 (en) * | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
| US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
| CA2737241C (en) * | 2008-09-26 | 2017-08-29 | Ucb Pharma S.A. | Multivalent antibody fusion proteins |
| CA2771336C (en) * | 2009-09-15 | 2019-11-26 | The Board Of Trustees Of The Leland Stanford Junior University | Synergistic anti-cd47 therapy for hematologic cancers |
| EP2791170A1 (en) * | 2011-12-16 | 2014-10-22 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
| DK3725807T3 (da) * | 2012-12-03 | 2026-01-12 | Novimmune Sa | Anti-cd47 antistoffer og fremgangsmåder til anvendelse deraf |
| US20140213771A1 (en) * | 2012-12-28 | 2014-07-31 | Abbvie, Inc. | Multi-specific binding proteins |
| JP2016514676A (ja) * | 2013-03-15 | 2016-05-23 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 四価二重特異性抗体 |
| US10519251B2 (en) * | 2013-12-30 | 2019-12-31 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| WO2016022971A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Sirp alpha-antibody fusion proteins |
| PL3180363T3 (pl) * | 2014-08-15 | 2020-02-28 | Merck Patent Gmbh | Białka fuzyjne immunoglobulin sirp-alfa |
| WO2017053423A1 (en) * | 2015-09-21 | 2017-03-30 | Erasmus University Medical Center | Anti-cd47 antibodies and methods of use |
| CN107459579B (zh) * | 2016-06-01 | 2021-09-24 | 泰州迈博太科药业有限公司 | 一种靶向egfr和cd47双特异性融合蛋白、制备方法及应用 |
| CA3035427A1 (en) * | 2016-09-01 | 2018-03-08 | Umc Utrecht Holding B.V. | Cd20 antibodies |
| WO2018137705A1 (en) * | 2017-01-26 | 2018-08-02 | Zai Lab (Shanghai) Co., Ltd. | Cd47 antigen binding unit and uses thereof |
| EP3747438A1 (en) * | 2017-07-24 | 2020-12-09 | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis | Treating pathological conditions by direct and indirect targeting of sirpa - cd47 interaction |
| IL272418B2 (en) * | 2017-08-08 | 2024-09-01 | Hoffmann La Roche | Abinotuzumab treatment of a new subgroup of DLBCL patients |
-
2019
- 2019-10-29 CN CN201980087109.4A patent/CN113260632A/zh active Pending
- 2019-10-29 EP EP19879444.8A patent/EP3873942A4/en active Pending
- 2019-10-29 CA CA3118312A patent/CA3118312A1/en active Pending
- 2019-10-29 KR KR1020217016137A patent/KR20210096612A/ko not_active Ceased
- 2019-10-29 JP JP2021524345A patent/JP2022506761A/ja active Pending
- 2019-10-29 GB GB2107478.6A patent/GB2596411B/en active Active
- 2019-10-29 AU AU2019369397A patent/AU2019369397A1/en active Pending
- 2019-10-29 WO PCT/US2019/058648 patent/WO2020092427A1/en not_active Ceased
-
2021
- 2021-04-28 US US17/242,793 patent/US20210332131A1/en active Pending
-
2024
- 2024-08-26 JP JP2024144789A patent/JP2024170456A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022506761A5 (https=) | ||
| CN102741282B (zh) | 针对转铁蛋白受体的抗体以及其用于依赖于铁的肿瘤的免疫疗法的用途 | |
| CN110914306B (zh) | 检查点抑制物双特异性抗体 | |
| JP6359372B2 (ja) | ＤＡＲＰｉｎを含む二重特異キメラ蛋白質 | |
| JP2021508469A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2022515318A5 (https=) | ||
| JP2021524268A5 (https=) | ||
| JP2018503380A5 (https=) | ||
| JP2020504723A5 (https=) | ||
| RU2019123613A (ru) | Биспецифические антигенсвязывающие молекулы, содержащие антитело к4-1вв, клон 20н4.9 | |
| JP2010536378A5 (https=) | ||
| JP2021510521A5 (https=) | ||
| JP2018502050A5 (https=) | ||
| US12168690B2 (en) | Anti-EGFR/anti-4-1BB bispecific antibody | |
| FI3941946T3 (fi) | Klaudiini-6-vasta-aineita ja klaudiini-6-vasta-ainelääkekonjugaatteja | |
| JP2010509931A5 (https=) | ||
| WO2012057288A1 (ja) | 新規抗ｄｒ５抗体 | |
| JP2021508707A5 (https=) | ||
| JP2025503322A5 (https=) | ||
| JP2023549537A5 (https=) | ||
| JP2022545741A5 (https=) | ||
| CA3208455A1 (en) | Novel anti-gremlin1 antibodies | |
| GB2596411A (en) | Compositions and methods comprising IgA antibody constructs | |
| JP2023549316A5 (https=) |